GGrantIndex
Sort

64,565 grants matching drug discovery

Hydrogel-enabled self-assembled human brain organoids for neurotoxicity applications

$930,433
Connie S Lebakken · Stem Pharm, Inc. · R44 · FY2021 · ES

Molecular Pathogenesis of Neoplasia

$930,329
Russell Lonser · National Institute Of Neurological Disorders And Stroke · ZIA · FY2012 · NS

Mechanisms of DNA Homology-directed Genome Repair and Tumor Suppression

$930,000
Patrick Sung · University Of Texas Hlth Science Center · R35 · FY2025 · CA

Mechanisms of DNA Homology-directed Genome Repair and Tumor Suppression

$930,000
Patrick Sung · University Of Texas Hlth Science Center · R35 · FY2021 · CA

A High Throughput Biofilm Assay System

$929,976
Cristian Ionescu-Zanetti · Fluxion Biosciences, Inc. · R44 · FY2009 · GM

Optimized Ratiometric Voltage-Sensitive Dyes for Cardiac Research, Safety Pharmacology

$929,918
Corey Acker · Potentiometric Probes, Llc · R44 · FY2024 · GM

Designer Drugs: The Emerging Face of Drug Abuse

$929,824
Marilyn A Huestis · National Institute On Drug Abuse · ZIA · FY2014 · DA

High Sensitivity NMR Spectrometer with Cryoprobe

$929,724
Joseph M Fox · University Of Delaware · S10 · FY2019 · OD

Discovery of solubilizing side chains for in vivo release of diverse drug classes using the Click Activated Protodrugs (CAP) platform

$929,651
Nathan Yee · Tambo, Inc. · R44 · FY2024 · TR

UT Southwestern Center for Translational Medicine (UL1/KL2/TL1

$929,591
Robert Daniel Toto · Ut Southwestern Medical Center · KL2 · FY2014 · TR

Tetracycline derivatives as SMN2 mRNA splicing modifiers for treatment of SMA.

$929,373
Paul J Higgins · Paratek Pharmaceuticals · U01 · FY2009 · NS

Tetracycline derivatives as SMN2 mRNA splicing modifiers for treatment of SMA.

$929,373
Paul Higgins · Paratek Pharmaceuticals · U01 · FY2009 · NS

Disease Modifying Biologics for Rheumatoid Arthritis

$929,079
Rekha Bansal · Novelmed Therapeutics, Inc. · R44 · FY2011 · AG

Specificity Screening Drug Development Tool for Biotherapeutic Safety

$929,016
Benjamin Jacob Doranz · Integral Molecular · SB1 · FY2025 · GM

Novel PK/PD Strategies for Polymyxin Combinations against Gram-negative Superbugs

$928,854
Brian Tsuji · State University Of New York At Buffalo · R01 · FY2016 · AI

Attacking stress tolerance in cancer

$928,703
David A Cheresh · University Of California, San Diego · R35 · FY2022 · CA

Developmental Biology and Solid Tumor

$928,558
Richard James Gilbertson · St. Jude Children'S Research Hospital · P30 · FY2014 · CA

Development of Sudaxine for the Treatment of Opioid Induced Respiratory Depression (OIRD) in the Peri-operative Hospital Setting

$928,464
James N Bates · Atelerix Life Sciences Inc. · R44 · FY2023 · HL

Identifying Genetic Variants Associated with Opioid Overdose Mortality

$928,386
Elliot C Nelson · Washington University · R01 · FY2018 · DA

Novel Functions of Lung Macrophages and Fibroblasts in Pulmonary Inflammation and Fibrosis

$928,378
Marc L Peters-Golden · University Of Michigan At Ann Arbor · R35 · FY2022 · HL

Novel Functions of Lung Macrophages and Fibroblasts in Pulmonary Inflammation and Fibrosis

$928,378
Marc L Peters-Golden · University Of Michigan At Ann Arbor · R35 · FY2019 · HL

Novel Functions of Lung Macrophages and Fibroblasts in Pulmonary Inflammation and Fibrosis

$928,378
Marc L Peters-Golden · University Of Michigan At Ann Arbor · R35 · FY2021 · HL

Novel Functions of Lung Macrophages and Fibroblasts in Pulmonary Inflammation and Fibrosis

$928,378
Marc L Peters-Golden · University Of Michigan At Ann Arbor · R35 · FY2020 · HL

Lung-on-a-Chip Disease Models for Efficacy Testing (COVID-19 Competitive Revision)

$928,351
Donald E Ingber · Harvard University · UH3 · FY2020 · HL

Tackling Undruggable Cancer Targets using Chemoproteomic Platforms

$928,230
Daniel Nomura · University Of California Berkeley · R35 · FY2022 · CA